Bicycle Therapeutics plc (NASDAQ:BCYC) Given Consensus Rating of “Moderate Buy” by Analysts

Bicycle Therapeutics plc (NASDAQ:BCYC) has received an average rating of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $46.86.

BCYC has been the topic of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, April 10th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of Bicycle Therapeutics in a research report on Friday. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $60.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, February 21st.

Bicycle Therapeutics Trading Down 0.4 %

Shares of BCYC opened at $24.58 on Friday. Bicycle Therapeutics has a 12 month low of $12.54 and a 12 month high of $28.91. The stock’s 50-day moving average is $24.02 and its two-hundred day moving average is $19.47. The company has a debt-to-equity ratio of 0.08, a current ratio of 8.08 and a quick ratio of 8.08. The stock has a market cap of $738.46 million, a PE ratio of -5.52 and a beta of 0.90.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.63. The firm had revenue of $19.53 million during the quarter, compared to analysts’ expectations of $6.06 million. Bicycle Therapeutics had a negative return on equity of 50.10% and a negative net margin of 404.14%. The business’s quarterly revenue was up 298.9% on a year-over-year basis. Equities analysts forecast that Bicycle Therapeutics will post -5.2 earnings per share for the current fiscal year.

Insider Activity at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 3,158 shares of Bicycle Therapeutics stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $23.81, for a total value of $75,191.98. Following the completion of the transaction, the chief executive officer now directly owns 387,270 shares of the company’s stock, valued at approximately $9,220,898.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders have sold 5,312 shares of company stock valued at $126,139. Corporate insiders own 10.20% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Platinum Investment Management Ltd. bought a new stake in Bicycle Therapeutics in the 3rd quarter valued at about $5,735,000. Deutsche Bank AG boosted its position in shares of Bicycle Therapeutics by 1,051.4% during the third quarter. Deutsche Bank AG now owns 96,370 shares of the company’s stock worth $1,936,000 after buying an additional 88,000 shares during the period. Braidwell LP bought a new position in Bicycle Therapeutics in the 3rd quarter worth approximately $25,914,000. Exchange Traded Concepts LLC increased its position in Bicycle Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 6,727 shares of the company’s stock valued at $122,000 after acquiring an additional 1,706 shares during the period. Finally, Polar Capital Holdings Plc increased its position in Bicycle Therapeutics by 33.2% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,011,500 shares of the company’s stock valued at $20,321,000 after acquiring an additional 252,000 shares during the period. Institutional investors own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.